Top-Rated StocksTop-RatedNASDAQ:CRNX Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis $50.39 -0.59 (-1.16%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$49.67▼$51.6650-Day Range$43.83▼$54.9852-Week Range$15.76▼$55.78Volume597,270 shsAverage Volume793,252 shsMarket Capitalization$3.97 billionP/E RatioN/ADividend YieldN/APrice Target$64.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Crinetics Pharmaceuticals alerts: Email Address Crinetics Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.92 Rating ScoreUpside/Downside28.5% Upside$64.75 Price TargetShort InterestBearish8.20% of Shares Sold ShortDividend StrengthN/ASustainability-0.62Upright™ Environmental ScoreNews Sentiment1.03Based on 6 Articles This WeekInsider TradingSelling Shares$8.34 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.72) to ($3.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.52 out of 5 starsMedical Sector246th out of 910 stocksPharmaceutical Preparations Industry106th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingCrinetics Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.92, and is based on 11 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCrinetics Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Crinetics Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.20% of the outstanding shares of Crinetics Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverCrinetics Pharmaceuticals has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Crinetics Pharmaceuticals has recently increased by 5.72%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCrinetics Pharmaceuticals does not currently pay a dividend.Dividend GrowthCrinetics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCrinetics Pharmaceuticals has received a 46.37% net impact score from Upright. Crinetics Pharmaceuticals seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Crinetics Pharmaceuticals is -0.62. Previous Next 2.8 News and Social Media Coverage News SentimentCrinetics Pharmaceuticals has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Crinetics Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for CRNX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Crinetics Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Crinetics Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,337,942.00 in company stock.Percentage Held by InsidersOnly 6.00% of the stock of Crinetics Pharmaceuticals is held by insiders.Percentage Held by Institutions98.51% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Crinetics Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($3.72) to ($3.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Crinetics Pharmaceuticals is -13.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Crinetics Pharmaceuticals is -13.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCrinetics Pharmaceuticals has a P/B Ratio of 4.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Crinetics Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.Read More CRNX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRNX Stock News HeadlinesAugust 29, 2024 | insidertrades.comInsider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells 3,000 Shares of StockSeptember 5 at 3:20 AM | msn.comCrinetics Pharmaceuticals, Inc. (CRNX): Among the Best Mid-Cap Healthcare Stocks To Buy NowSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.September 3, 2024 | americanbankingnews.comBrokerages Set Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) PT at $64.75August 31, 2024 | americanbankingnews.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $159,570.00 in StockAugust 30, 2024 | finance.yahoo.comCrinetics Pharmaceuticals to Participate in Two Upcoming Investor ConferencesAugust 28, 2024 | finance.yahoo.comInsider Sale: Chief Scientific Officer Stephen Betz Sells 3,000 Shares of Crinetics ...August 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Crinetics Pharmaceuticals on Strong Pipeline and Regulatory ProgressSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.August 12, 2024 | globenewswire.comCrinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 12, 2024 | seekingalpha.comCrinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage BiotechAugust 9, 2024 | markets.businessinsider.comBuy Rating for Crinetics Pharmaceuticals: Strong Pipeline and Financial StabilityAugust 9, 2024 | finanznachrichten.deCrinetics Pharmaceuticals, Inc.: Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment ChallengesAugust 9, 2024 | benzinga.comA Closer Look at 11 Analyst Recommendations For Crinetics PharmaceuticalsAugust 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Eli Lilly & Co (LLY)August 9, 2024 | seekingalpha.comCrinetics Pharmaceuticals, Inc. (CRNX) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | finance.yahoo.comCrinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 9, 2024 | msn.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q2 2024 Earnings Call TranscriptSee More Headlines Receive CRNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CRNX CUSIPN/A CIK1658247 Webwww.crinetics.com Phone(858) 450-6464FaxN/AEmployees210Year FoundedN/APrice Target and Rating Average Stock Price Target$64.75 High Stock Price Target$97.00 Low Stock Price Target$35.00 Potential Upside/Downside+28.5%Consensus RatingModerate Buy Rating Score (0-4)2.92 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($3.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-214,530,000.00 Net MarginsN/A Pretax Margin-18,257.91% Return on Equity-37.03% Return on Assets-32.41% Debt Debt-to-Equity RatioN/A Current Ratio16.09 Quick Ratio16.09 Sales & Book Value Annual Sales$1.39 million Price / Sales2,869.14 Cash FlowN/A Price / Cash FlowN/A Book Value$10.38 per share Price / Book4.85Miscellaneous Outstanding Shares78,860,000Free Float74,128,000Market Cap$3.97 billion OptionableOptionable Beta0.63 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. R. Scott Struthers Ph.D. (Age 61)Founder, President, CEO & Director Comp: $978.34kDr. Stephen F. Betz Ph.D. (Age 58)Founder & Chief Scientific Officer Comp: $672.66kMr. Marc J. C. Wilson (Age 45)Chief Financial Officer Comp: $642.25kMr. Jeff E. Knight (Age 53)Chief Operating Officer Comp: $657.31kDr. Alan S. Krasner M.D. (Age 61)Chief Endocrinologist Comp: $653.92kMr. James Hassard (Age 58)Chief Commercial Officer Comp: $623.5kMs. Garlan AdamsGeneral Counsel & Corporate SecretaryMs. Adriana Cabre M.B.A.Chief Human Resources OfficerMr. Kevin CappsHead of Intellectual PropertyMr. Chris Robillard M.B.A.Chief Business OfficerMore ExecutivesKey CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLIonis PharmaceuticalsNASDAQ:IONSBicycle TherapeuticsNASDAQ:BCYCAeglea BioTherapeuticsNASDAQ:AGLEViatrisNASDAQ:VTRSView All CompetitorsInsiders & InstitutionsStephen F BetzSold 3,000 sharesTotal: $159,570.00 ($53.19/share)Novo Holdings A SSold 98,600 shares on 8/20/2024Ownership: 1.268%Senator Investment Group LPBought 135,000 shares on 8/20/2024Ownership: 0.171%Point72 Asset Management L.P.Sold 2,168,630 shares on 8/19/2024Ownership: 3.526%Algert Global LLCBought 6,667 shares on 8/16/2024Ownership: 0.053%View All Insider TransactionsView All Institutional Transactions CRNX Stock Analysis - Frequently Asked Questions How have CRNX shares performed this year? Crinetics Pharmaceuticals' stock was trading at $35.58 at the start of the year. Since then, CRNX shares have increased by 41.6% and is now trading at $50.39. View the best growth stocks for 2024 here. How were Crinetics Pharmaceuticals' earnings last quarter? Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.08. The firm's quarterly revenue was down 59.6% on a year-over-year basis. What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO? 6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend. When did Crinetics Pharmaceuticals IPO? Crinetics Pharmaceuticals (CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO. Who are Crinetics Pharmaceuticals' major shareholders? Top institutional investors of Crinetics Pharmaceuticals include Driehaus Capital Management LLC (7.75%), Point72 Asset Management L.P. (3.53%), Point72 Asset Management L.P. (3.53%) and First Light Asset Management LLC (1.52%). Insiders that own company stock include Perceptive Advisors Llc, Richard Scott Struthers, Marc Wilson, Stephen F Betz, Jeff E Knight, Alan Seth Krasner, Dana Pizzuti, Matthew K Fust, Coelho Rogerio Vivaldi and Ajay Madan. View institutional ownership trends. How do I buy shares of Crinetics Pharmaceuticals? Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Crinetics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC) and Selecta Biosciences (SELB). This page (NASDAQ:CRNX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
